Categories
Markets

ACST Stock – (NASDAQ: ACST) is actually providing an update on the use

ACST Stock – (NASDAQ: ACST) is actually providing an update on the usage

ACST
-1.84%
As necessary pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or maybe the “Company”) ACST Stock (NASDAQ: ACST – TSX V: ACST) is providing an update on the usage of the “at-the market” equity of its offering plan.

As earlier disclosed, Acasti entered into an amended and restated ATM sales agreement on June 29, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. along with H.C. Co. and Wainwright, LLC (collectively, the “Agents”), to carry out a “at the market” equity offering system under which Acasti might issue as well as market from time to time its common shares having an aggregate offering price of up to seventy five dolars million through the Agents (the “ATM Program”).

ACST Stock – Pursuant to the ATM Program, as required pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the final distributions reported on January 27, 2021, Acasti issued an aggregate of 20,159,229 typical shares (the “ATM Shares”) with the NASDAQ Stock Market for aggregate gross proceeds to the Company of US$21.7 million. The ATM Shares had been offered at prevailing market prices averaging US$1.0747 a share. No securities were sold through the facilities of the TSXV or maybe, to the understanding of the Company, in Canada. The ATM Shares were sold pursuant to a U.S. registration statement on Form S 3 (No. 333 239538) as made effective on July seven, 2020, and the Sales Agreement. Pursuant to the Sales Agreement, a money commission of 3.0 % on the aggregate yucky proceeds raised was paid to the Agents in connection with the services of theirs. As a direct result of the latest ATM sales, Acasti has a total of 200,119,659 common shares issued and great as of March 5, 2021.

The extra capital raised has strengthened Acasti’s balance sheet and will provide the Company with more freedom in its ongoing review process to explore and evaluate strategic options.

About Acasti – ACST Stock

Acasti is actually a biopharmaceutical innovator that has historically focused on the research, commercialization and development of prescription drugs making use of OM3 greasy acids delivered both as totally free fatty acids and bound-to-phospholipid esters, produced from krill oil. OM3 fatty acids have extensive clinical evidence of safety and efficacy for lowering triglycerides in patients with hypertriglyceridemia, or HTG. CaPre, an OM3 phospholipid therapeutic, was being created for people with serious HTG.

Forward Looking Statements – ACST Stock

Statements of this press release which are not statements of current or historical truth constitute “forward looking information” to the meaning of Canadian securities laws and “forward looking statements” within the meaning of U.S. federal securities laws (collectively, “forward-looking statements”). Such forward-looking assertions include known and unknown risks, uncertainties, along with other unknown variables that may cause the actual results of Acasti to be materially different from historical outcomes and even from any later results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are actually urged to consider statements marked with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or any other related expressions to be uncertain and forward-looking. People are actually cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Forward-looking statements in this press release include, but are not confined to, information or statements about Acasti’s strategy, succeeding operations as well as the review of its of strategic options.

The forward looking assertions contained in this specific press release are expressly qualified in the entirety of theirs by this alerting statement, the “Special Note Regarding Forward-Looking Statements” section in Acasti’s latest annual report on Form 10 K and quarterly report on Form 10-Q, which are actually readily available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at giving www.sedar.com as well as on the investor aisle of Acasti’s site at www.acastipharma.com. All forward looking claims in this press release are produced as of the date of this particular press release.

ACST Stock – Acasti does not undertake to upgrade any such forward looking statements whether as a result of information that is brand new , future events or otherwise, except as needed by law. The forward-looking statements contained herein are also subject typically to risks and assumptions as well as uncertainties that are discussed from time to time in Acasti’s public securities filings with the Securities as well as The Canadian and exchange Commission securities commissions, including Acasti’s latest annual report on Form 10-K and quarterly report on Form 10 Q under the caption “Risk Factors“.

 

ACST Stock – (NASDAQ: ACST) is actually providing an update on the usage

Leave a Reply

Your email address will not be published. Required fields are marked *